公开(公告)号：EP1741789A1

公开(公告)日：2007-01-10

申请号：EP06013756.9

申请日：1997-03-12

申请人： CYANAMID IBERICA, SA

发明人： Enjuanes Sanchez, Luis ,  Plana Duran, Juan ,  Alonso Villanueva, Sara ,  Ballesteros Jarreno, M. Luisa ,  Castilla Castrillon, Joaquin ,  Gonzales Martinez, José Manuel ,  Izeta Parmesan, Ander ,  Mendez Zuzunegui, Ana ,  Muntion Saenz, Maria ,  Pénzes, Zoltán, Ph.D. ,  Sanchez Morgado, José Manuel ,  Sanchez Sanchez, Carlos Miguel ,  Smerdou Picazo, Cristian ,  Gurpegui, Isobel Sola

IPC分类号： C12N15/86 ,  C12N7/01 ,  A61K39/225 ,  A61K39/215 ,  A61K35/76

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61K39/225 ,  A61K2039/5254 ,  A61K2039/53 ,  A61K2039/542 ,  A61K2039/552 ,  C07K16/10 ,  C07K2317/76 ,  C12N7/00 ,  C12N15/86 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2770/20064

摘要： The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses or an antibody conferring protection against an infectious agent. The defective viral genome comprises the genome of a parental virus having the viral replicase recognition signals located on ends 3' and 5', further comprising internal deletions, and wherein said defective viral genome depends on a helper virus for its replication and encapsidation. These vectors are suitable for the forming of a recombinant system comprising the aforesaid expression vector, and a helper virus. The system is suitable for the manufacture of mono- and polyvalent vaccines against infectious agents of different animal species, especially pigs, dogs and cats, and as expression vehicles for antibodies protective against infectious agents.

摘要翻译： 所述载体包含重组缺陷病毒基因组中表达适合的全身和分泌免疫应答的诱导或抗体在感染剂赋予针对保护的至少一种抗原。 有缺陷的病毒基因组包括具有位于端部3“和5”，还包括内部缺失的病毒复制酶识别信号的亲本病毒的基因组中，和所述worin缺陷病毒基因组依赖于辅助病毒其复制和衣壳化。 这些载体适用于重组系统包括上述的表达载体，和辅助病毒的形成。 该系统适合于针对不同的动物物种的感染性物质，爱特别是猪，狗和猫的单 - 和多价疫苗的制造中，并作为抗体针对传染剂的保护表达载体。

公开(公告)号：EP1470218A2

公开(公告)日：2004-10-27

申请号：EP02738952.7

申请日：2002-05-17

申请人： Universiteit Utrecht ,  STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN

发明人： ROTTIER, Petrus, Josephus, Marie ,  DE HAAN, Cornelis, Alexander, Maria ,  HAIJEMA, Bert, Jan ,  BOSCH, Berend, Jan

IPC分类号： C12N7/04 ,  C12N15/86 ,  A61K39/215 ,  A61K39/225 ,  C07K14/165

CPC分类号： A61K39/215 ,  A61K38/00 ,  A61K39/12 ,  A61K39/225 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/12034 ,  C12N2710/16034 ,  C12N2740/13034 ,  C12N2750/14334 ,  C12N2760/16034 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2800/204 ,  G01N33/56983 ,  G01N2333/165

摘要： The invention relates to the field of coronaviruses and diagnosis, therapeutic use and vaccines derived thereof. The invention provides replicative coronaviruses and replicative virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. Said deletion is preferably resulting in at least a functional deletion in that the corresponding gene is not or only partly expressed whereby the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product. One striking result seen with VLPs provided with deletions as provided herein is that said deleted VLP, albeit capable of replication in vitro and in vivo, are in general well attenuated, in that they do not cause disease in the target host, making them very suitable for therapeutic use, said as a delivery vehicle for genes and other cargo (whereby specific targeting may be provided as well when desired), and for use as a vaccine, being attenuated while carrying important immunogenic determinants that help elicit an immune response.

公开(公告)号：EP1234024B1

公开(公告)日：2004-05-19

申请号：EP00990628.0

申请日：2000-11-30

申请人： CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

发明人： ENJUANES SANCHEZ, Luis

IPC分类号： C12N7/04 ,  C12N15/70 ,  C12N1/21 ,  C12N15/50 ,  A61K39/215 ,  A61K39/225 ,  A61K39/295 ,  A61P31/12

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/225 ,  A61K2039/525 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/541 ,  C07K14/005 ,  C12N15/70 ,  C12N15/86 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2770/20062 ,  C12N2800/204 ,  C12N2800/80

摘要： The present invention relates to methods of preparing a DNA comprising steps, wherein (a) a DNA comprising a full length copy of the genomic RNA (gRNA) or an RNA virus; or (b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or (c) a DNA having a homology of at least 60% to the sequences of (a) or (b); is cloned into a bacterial artificial chromosome (BAC). Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or no-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can be assembled to a virion. Further, the use of these nucleic acids for preparation of viral RNA or virions as well as pharmaceutical preparations comprising these DNAs, viral RNAs or virions is disclosed.

公开(公告)号：EP0028804A2

公开(公告)日：1981-05-20

申请号：EP80106801.6

申请日：1980-11-05

申请人： IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

发明人： Gough, Patricia Marie

IPC分类号： A61K39/225

CPC分类号： A61K39/225 ,  A61K39/12 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55505 ,  A61K2039/55566 ,  C12N2770/20034

摘要： A vaccine for protecting swine against transmissible gastroenteritis (TGE) is prepared from a specific antigenic protein (SPA) obtained by separation from TGE virus. The SPA is characterized by the buoyant density of 1.02 to 1.03 gm/ml in a solution of sucrose and an Rf value of approximately 1.84 relative to human serum albumin. The vaccine may be prepared in parenteral dose form for administration to pregnant sows, thereby effectively protecting the baby pigs against fatal TGE infection.

摘要翻译： 从通过分离TGE病毒获得的特异性抗原蛋白（SPA）制备用于保护猪免于传染性胃肠炎（TGE）的疫苗。 SPA的特征在于蔗糖溶液中的浮游密度为1.02至1.03gm / ml，相对于人血清白蛋白的Rf值约为1.84。 疫苗可以以胃肠外剂量形式制备用于给予母猪，从而有效地保护婴儿免受致命的TGE感染。

公开(公告)号：EP1470218B1

公开(公告)日：2010-07-07

申请号：EP02738952.7

申请日：2002-05-17

申请人： Universiteit Utrecht ,  Stichting voor de Technische Wetenschappen

发明人： ROTTIER, Petrus, Josephus, Marie ,  DE HAAN, Cornelis, Alexander, Maria ,  HAIJEMA, Bert, Jan ,  BOSCH, Berend, Jan

IPC分类号： C12N7/04 ,  C12N15/86 ,  A61K39/215 ,  A61K39/225 ,  C07K14/165

CPC分类号： A61K39/215 ,  A61K38/00 ,  A61K39/12 ,  A61K39/225 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/12034 ,  C12N2710/16034 ,  C12N2740/13034 ,  C12N2750/14334 ,  C12N2760/16034 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2800/204 ,  G01N33/56983 ,  G01N2333/165

公开(公告)号：EP1651271A4

公开(公告)日：2006-11-08

申请号：EP04749378

申请日：2004-03-12

申请人： INTERMUNE INC

发明人： BLATT LAWRENCE M

IPC分类号： A61K38/21 ,  A61K20060101 ,  A61K31/7056 ,  A61K39/215 ,  A61K39/225 ,  A61K45/00 ,  A61K47/00 ,  A61K47/30 ,  A61P11/00 ,  A61P31/12 ,  A61P31/14

CPC分类号： A61K31/7056 ,  A61K38/212 ,  A61K38/217 ,  A61K2300/00

摘要： The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection.

公开(公告)号：EP1651271A2

公开(公告)日：2006-05-03

申请号：EP04749378.8

申请日：2004-03-12

申请人： Intermune, Inc.

发明人： BLATT, Lawrence, M.

IPC分类号： A61K47/30 ,  A61K47/00 ,  A61K45/00 ,  A61K39/215 ,  A61K39/225

CPC分类号： A61K31/7056 ,  A61K38/212 ,  A61K38/217 ,  A61K2300/00

摘要： The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection.

公开(公告)号：EP0310316B1

公开(公告)日：1995-02-01

申请号：EP88308907.0

申请日：1988-09-26

申请人： Beecham Inc.

发明人： Bordt, Dale, c/o Beecham Laboratories ,  Draayer, Hans Beecham Inc., Beecham Laboratories

IPC分类号： A61K39/225 ,  A61K39/295 ,  C12N7/06

CPC分类号： A61K39/12 ,  A61K39/155 ,  A61K39/225 ,  A61K39/265 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/20034 ,  C12N2770/20063

公开(公告)号：EP3432922A1

公开(公告)日：2019-01-30

申请号：EP17714145.4

申请日：2017-03-21

申请人： South Dakota Board of Regents ,  Universidade Federal de Santa Maria

发明人： DIEL, Diego G. ,  FLORES, Eduardo F.

IPC分类号： A61K39/205 ,  A61K39/225 ,  A61K39/275 ,  C12N15/86

摘要： The present invention is directed to novel vaccine delivery platform based on the Orf virus (ORFV) genome, which carry heterologous antigens, methods of making and methods of using the same for prevention of infections, diseases, and other conditions in animals.

公开(公告)号：EP1437400A2

公开(公告)日：2004-07-14

申请号：EP04007406.4

申请日：2000-11-30

申请人： CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

发明人： The designation of the inventor has not yet been filed

IPC分类号： C12N7/04 ,  C12N15/70 ,  C12N1/21 ,  C12N15/50 ,  A61K39/215 ,  A61K39/225 ,  A61K39/295 ,  A61P31/12

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/225 ,  A61K2039/525 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/541 ,  C07K14/005 ,  C12N15/70 ,  C12N15/86 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2770/20062 ,  C12N2800/204 ,  C12N2800/80

摘要： The present invention relates to methods of preparing a DNA comprising steps, wherein

(a) a DNA comprising a full length copy of the genomic RNA (gRNA) of an RNA virus; or
(b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or
(c) a DNA having a homology of at least 60% to the sequences of (a) or (b);
is cloned into a bacterial artificial chromosome (BAC).
Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or non-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can be assembled to a virion.
Further, the use of these nucleic acids for preparation of viral RNA or virions as well as pharmaceutical preparations comprising these DNAs, viral RNAs or virions is disclosed.

摘要翻译： 本发明涉及制备DNA的方法，包括步骤，其中（a）包含RNA病毒的基因组RNA（gRNA）的全长拷贝的DNA; 或（b）包含RNA病毒的gRNA的一个或几个片段的DNA，其对于RNA依赖性RNA聚合酶和至少一种结构或非结构蛋白的片段编码; 或（c）与（a）或（b）的序列具有至少60％同源性的DNA; 克隆到细菌人造染色体（BAC）中。 另外，提供了DNA，其包含衍生自冠状病毒的基因组RNA（gRNA）的序列，该序列与病毒的天然序列具有至少60％的同源性，并编码RNA依赖性RNA聚合酶， 至少一种结构或非结构蛋白，其中所述DNA的片段能够被转录成RNA，所述RNA可以组装成病毒粒子。 此外，公开了这些核酸用于制备病毒RNA或病毒粒子以及包含这些DNA，病毒RNA或病毒粒子的药物制剂的用途。